Caplyta vs Latuda
A side-by-side look at two mental health medications advertised on TV. Informational only — not medical advice.
| US Caplyta | US Latuda | |
|---|---|---|
| Generic name | lumateperone | lurasidone |
| Drug class | Atypical Antipsychotic | Atypical Antipsychotic |
| Treats | Schizophrenia, bipolar depression | Schizophrenia, bipolar depression |
| Category | Mental Health | Mental Health |
| Manufacturer | Intra-Cellular Therapies | Sunovion (Sumitomo) |
| Year approved | 2019 | 2010 |
| FDA warning | Black box warning | Black box warning |
| Est. TV ad spend | $130M | $85M |
| Common side effects | Drowsiness, Dry mouth, Dizziness, Nausea | Sleepiness, Restlessness, Nausea, Movement problems |
Frequently asked questions
Is Caplyta or Latuda better?
Neither is universally "better." Caplyta (lumateperone) and Latuda (lurasidone) are both used for mental health, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Caplyta and Latuda?
Caplyta is a Atypical Antipsychotic made by Intra-Cellular Therapies, while Latuda is a Atypical Antipsychotic made by Sunovion (Sumitomo). See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Caplyta has the larger estimated TV advertising budget of the two.